These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 29530598)

  • 1. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
    Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
    Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
    Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
    Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
    Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
    FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.
    Fiorucci S; Antonelli E; Rizzo G; Renga B; Mencarelli A; Riccardi L; Orlandi S; Pellicciari R; Morelli A
    Gastroenterology; 2004 Nov; 127(5):1497-512. PubMed ID: 15521018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
    Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.
    Fickert P; Fuchsbichler A; Moustafa T; Wagner M; Zollner G; Halilbasic E; Stöger U; Arrese M; Pizarro M; Solís N; Carrasco G; Caligiuri A; Sombetzki M; Reisinger E; Tsybrovskyy O; Zatloukal K; Denk H; Jaeschke H; Pinzani M; Trauner M
    Am J Pathol; 2009 Dec; 175(6):2392-405. PubMed ID: 19910507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.
    Fiorucci S; Rizzo G; Antonelli E; Renga B; Mencarelli A; Riccardi L; Orlandi S; Pruzanski M; Morelli A; Pellicciari R
    J Pharmacol Exp Ther; 2005 Aug; 314(2):584-95. PubMed ID: 15860571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
    Fiorucci S; Rizzo G; Antonelli E; Renga B; Mencarelli A; Riccardi L; Morelli A; Pruzanski M; Pellicciari R
    J Pharmacol Exp Ther; 2005 Oct; 315(1):58-68. PubMed ID: 15980055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts.
    Renga B; Mencarelli A; Migliorati M; Cipriani S; D'Amore C; Distrutti E; Fiorucci S
    Inflamm Res; 2011 Jun; 60(6):577-87. PubMed ID: 21279417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin inhibits the nuclear translocation of Smad3 via interleukin-1beta signaling in hepatic stellate cells.
    Park JH; Kim J; Choi SY; Lee B; Lee JE; Park H; Moon JW; Park SH; Lee JM; Lee HS; Oh J
    Sci Rep; 2021 Feb; 11(1):3196. PubMed ID: 33542418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
    Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice.
    Yan J; Tung HC; Li S; Niu Y; Garbacz WG; Lu P; Bi Y; Li Y; He J; Xu M; Ren S; Monga SP; Schwabe RF; Yang D; Xie W
    Gastroenterology; 2019 Sep; 157(3):793-806.e14. PubMed ID: 31170413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiatherosclerotic effect of farnesoid X receptor.
    Mencarelli A; Renga B; Distrutti E; Fiorucci S
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis.
    Cipriani S; Carino A; Masullo D; Zampella A; Distrutti E; Fiorucci S
    Sci Rep; 2017 Jan; 7():41055. PubMed ID: 28117422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazoline I2 receptor inhibitor idazoxan regulates the progression of hepatic fibrosis via Akt-Nrf2-Smad2/3 signaling pathway.
    Xuanfei L; Hao C; Zhujun Y; Yanming L; Jianping G
    Oncotarget; 2017 Mar; 8(13):21015-21030. PubMed ID: 28423499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
    J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis.
    Lee JI; Wright JH; Johnson MM; Bauer RL; Sorg K; Yuen S; Hayes BJ; Nguyen L; Riehle KJ; Campbell JS
    Am J Physiol Cell Physiol; 2016 Mar; 310(6):C436-45. PubMed ID: 26632601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liuweiwuling tablets attenuate BDL-induced hepatic fibrosis via modulation of TGF-β/Smad and NF-κB signaling pathways.
    Liu H; Dong F; Li G; Niu M; Zhang C; Han Y; He L; Yin P; Wang B; Sang X; Li R; Wang J; Bai Z; Xiao X
    J Ethnopharmacol; 2018 Jan; 210():232-241. PubMed ID: 28864168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.